Batm Advanced Communicat... Share Discussion Threads

[doccash] 17/3/2021 10:30

Watching science and technology select committee . Dominic Cummings giving his views. Please forget cheap politics as this is not the place. One of his proposed proposals going forward is mass distribution of testing at home. A recent saliva test from BATM would be the obvious solution. This is just talk now but in reality going forward for covid or the next dangerous pathogen this is going to be the solution

[doccash] 12/3/2021 22:27

Peanuts How much does a luxury cruise cabin charge?

[paulisi] 12/3/2021 21:37

Depends on size:A simple PCR machine like Bio-Rad T100 thermal cycler has a list price of 4912 USD (with a promotional price of 2595 USD in the US) as of Jan 30, 2019. The cost of rtPCR systems ranges anywhere from 15,000$ for some RotorGene models to over 90,000$ for QuantStudio 12k.

[cjpaul] 12/3/2021 11:41

For what is worth, the quick saliva test is a breakthrough and will be very successful. Data show that the sensitivity and specificity's are as good as those of the standard nasopharyngeal flocked swab PCR. Despite the vaccine we will have COVID with us for a long time as stated by FSE and it's most likely that sooner or later this will be the preferred PCR test. The markets reaction was muted but I am sure once people wake up to its potential it will respond. Will be buying on any dips. Thanks DocCash - I agree with you completely

[icemaninvestor] 12/3/2021 00:48

Anybody know how much the PCR instrument costs?

[fse] 11/3/2021 15:43

Price went up 7.5% on TASE ahead of London opening with higher volumes than we have seen lately. If you think this test is no longer needed might want to see the clip posted with Marom. he explains the relevance so suggest watching it.
Infectious diseases, their spread and mutation in a global trekking world is now the norm and we need to find ways of managing them. Accurate encompassing tests like this will aid vaccine development and treatments to counteract "specific" identified threats.

Any rate watch the interview.
Its posted above JD post 18289

[doccash] 11/3/2021 14:37

All standard PCR instruments can execute this test at a rate of c. 150-180 per hour, which (including the extraction phase) is approximately five times the rate for a nasopharyngeal test. One person is able to operate several instruments at the same time, which is very difficult with tests based on the existing swabbing methods. In addition, the instruments are able to be transported and set up in a mobile location.

So portable and answer in 1 hour

[paulisi] 11/3/2021 11:38

Interesting listen.Needs a mobile PCR with it, but can produce results within the hour.Accurate unlike the lateral tests and could be a substitute going forward.

[paulisi] 11/3/2021 10:31

Shares always ride early on via sentiment and then dip later in the day. Not just BATM. The majority.That is how the markets tends to work.Profit taking...

[paulisi] 11/3/2021 10:29

These are PCR tests so still need to be lab tested. They are not rapid tests.

[nellyb] 11/3/2021 10:17

also a proactiveinvestors video with zvi is now out.

[doccash] 11/3/2021 09:02

As a result, one operator can manage in excess of 1,000 tests per hour and can be deployed to where needed, such as the site of a school, sports event or on a cruise ship.

[doccash] 11/3/2021 08:58

Amazing share price goes down 10% on"sentiment" Now a cracking news update and just pops back a mere 10%.I'm not sure who said it's too late You can't have been watching wall to wall TV coverage saying how difficult the current lateral flow tests are for children in schools. You don't think the next organization planning such an extensive screen test program won't say let's try BATM

[danb45] 11/3/2021 08:36

all we need now is a nice big deal for the tests - great RNS today :-)

[boggy] 11/3/2021 08:16

Sorry, didn’t mean to post twice

[boggy] 11/3/2021 08:15

Paul’s - I don’t think it is too late in the day, have you seen the price rise recently at Avacta and they haven’t even said they can ship their tests yet (appreciate they are different tests)

[boggy] 11/3/2021 08:15

Paul’s - I don’t think it is too late in the day, have you seen the price rise recently at Avacta and they haven’t even said they can ship their tests yet (appreciate they are different tests)

[emeraldzebra] 11/3/2021 08:11

Oh. Why should it dip ?

[paulisi] 11/3/2021 08:08

Bumped to 100p, but expect to dip during the day.

[capitalist] 11/3/2021 07:21

I like the sound of it...

BATM launches no-swab saliva-based COVID-19 test

New self-collected saliva-based RT-PCR test significantly improves sample collection process and turnaround time while maintaining diagnostic accuracy

BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that it has launched a new molecular diagnostics kit that uses self-collected saliva samples to test for SARS-CoV-2 (COVID-19). This significantly improves the sample collection process compared with existing swabbing methods while, as an RT-PCR test, maintaining diagnostic accuracy. The Group has commenced taking orders and expects to begin delivering the kit in April.

This new kit, which is part of Adaltis' MOLgen product range, consists of reagents that have been developed to accurately detect SARS-CoV-2 in saliva samples that are collected by an individual chewing a cotton ball for 30 seconds and then spitting it (or spitting directly) into a small plastic collector tube (a Salivette). It uses the RT-PCR technique, which ensures the highest levels of diagnostic accuracy compared with other saliva-based tests currently available in the market that primarily use the lateral flow method, which are far less accurate causing many false negatives and positives.

The reagents are based on the Group's existing COVID-19 antigen kit that tests samples collected via swabbing the upper (via the nose) and middle parts of the throat or fluid from the lungs , and which has five (4+1) gene discovery capability (compared with most kits on the market having three gene discovery capability or less) to enable detection even with a very low viral load. The new test has 100% accuracy for both specificity and sensitivity.

By the individual collecting a saliva sample, the test can be administered without the need for any trained healthcare workers in full body personal protective equipment. The test also has the advantage of being non-invasive and comfortable compared with swabbing via the nose (nasopharyngeal swab) or back of the throat (oropharyngeal swab). As a result, it is a far simpler and quicker solution, and has particular benefits for testing children and people with disabilities where the existing swabbing methods can cause distress or the tests are not possible to administer at all.

Other benefits of the new test include:

-- Processing times at the laboratory are significantly reduced as the RNA extraction phase that is required for the existing swabbing methods before putting the samples into the PCR instrument is not needed for the Group's saliva-based test (which operates under a protocol developed at Yale University). The RNA extraction phase is also expensive and the main cause of contaminations that result in false diagnoses.

-- All standard PCR instruments can execute this test at a rate of c. 150-180 per hour, which (including the extraction phase) is approximately five times the rate for a nasopharyngeal test. One person is able to operate several instruments at the same time, which is very difficult with tests based on the existing swabbing methods. In addition, the instruments are able to be transported and set up in a mobile location. As a result, one operator can manage in excess of 1,000 tests per hour and can be deployed to where needed, such as the site of a school, sports event or on a cruise ship.

-- It negates the risk of false negatives that can arise due to a badly performed nasopharyngeal swab.

This new kit, which is CE certified, is able to detect all known variants of COVID-19, including in people who are asymptomatic. It has been validated by leading research and medical institutions in Italy.

The test can be processed using Adaltis' AMPLilab instrument or any standard PCR instrument. The Group can also provide the sample collectors.

Dr Zvi Marom, CEO of BATM, said:

"We are extremely proud to have launched this new saliva-based COVID-19 test for samples that are self-collected without the need for swabbing. This greatly simplifies the testing process to increase speed and reduce cost while maintaining the same high level of diagnostic accuracy. Despite the excellent progress that has been made with vaccinations, we believe that COVID-19 will be with us for quite some time and so solutions such as our new saliva test will be invaluable for providing the ongoing testing required in places where people gather such as schools and leisure venues. We have already received particular interest from cruise lines and professional sports teams who see this test as enabling a safe return to more normal life. We look forward to commence shipping this product shortly and to delivering further innovative diagnostic solutions for COVID-19 and other infectious diseases in the near future."

[paulisi] 11/3/2021 07:19

Another covid test kit announced.You just get the feeling, it's a bit late in the day.

[james dean] 10/3/2021 19:17

Agreed - divi soon.

[fse] 10/3/2021 18:45

haha nelly thats what I thought....
Share prices hardly ever follow any logical trend. We have all seen companies make huge positive announcements and the share price falls. Maybe it was priced in there ?
Also the positive news caused a run up and people took profits and not in a hurry to buy back until the price settles after profit taking... who knows.
Cant confirm this but I believe there could have been a major seller in Israel, Harel Insurance & Financial are shown having sold @6% of their holdings which amounted to sales 12M shares.

TASE prices stabilised somewhat today and ended marginally higher.

PER is around 60 which should not be demanding given the new products that they are releasing into the market place.
As I say I figure they should be in the 120p to 160p that does not mean to say they swing out of that range. At current share price they look attractive and 115p would be a BUY not a SELL option for me.